Advanced Cytoreduction as Surgical Standard of Care and Hyperthermic Intraperitoneal Chemotherapy as Promising Treatment in Epithelial Ovarian Cancer: Review of Literature Data

M. Deraco (1) , D. Baratti (1) , B. Laterza (1) , M.R. Balestra (1) , E. Mingrone (2) , Macrì (3) , S. Virzì (4) , F. Puccio (4) , P.S. Ravenda (5) , S. Kusamura (1)

1 Department of Surgery
2 Department of General Surgery and Emergency
3 Department of General Surgery
4 Department of General Surgery
5 Department of Medical Oncology

Favorable oncological outcomes have been reported in several trials with the introduction of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of Advanced Epithelial Ovarian Cancer (EOC). However most of the studies testing the combined approach are observational and has been conducted in inhomogeneous series so that the evidence supporting the performance of this combined treatment is still poor. Median Overall and Disease Free Survivals of up to 64 months and 57 months, respectively have been reported. Although a rate of morbidity of up to 40% has been observed in some series the CRS+HIPEC continues to gain an increased popularity. Several prospective randomized trials are ongoing using the procedure in various time points of the disease.

Mots clés: Cytoreductive Surgery; Peritonectomy; Hyperthermic Intraperitoneal Chemotherapy; Epithelial Ovarian Cancer; Peritoneal Carcinomatosis

M. Deraco, D. Baratti, B. Laterza, M.R. Balestra, E. Mingrone, et al.. Advanced Cytoreduction as Surgical Standard of Care and Hyperthermic Intraperitoneal Chemotherapy as Promising Treatment in Epithelial Ovarian Cancer: Review of Literature Data. EJSO - European Journal of Surgical Oncology, 2010, 37 (1), pp.4. ⟨10.1016/j.ejso.2010.11.004⟩. ⟨hal-00651629⟩